Denali Therapeutics Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio for
Neurodegeneration and Lysosomal Storage Diseases
January 9, 2023
Four programs expected to progress in late-stage clinical studies for MPS II (Hunter syndrome), ALS, and Parkinson’ disease
More here :
thanks for the post!
Annovis Bio Buntanetap Interim Analysis of the Parkinson's Clinical Study
Annovis Bio announced today the completion of patient enrollment for its phase III Parkinson’s Disease trial in a record nine months
Today we announced that the US FDA has cleared IND applications for 4dpharmaplc’s LiveBiotherapeutics MRx0005 and MRx0029, Phase I
Benfotiamine In The Mix For PD Again? 
The Extraordinary World of Music and the Mind
